Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins
- PMID: 11806806
- PMCID: PMC64823
- DOI: 10.1186/cvm-2-6-251
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins
Abstract
An explanation for the higher incidence of cardiovascular disease and heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) with doxazosin and the Vasodilator Heart Failure Trial (V-HeFT) with prazosin might be decreased expression of heat shock proteins. Heat shock proteins help to protect cells from ischemic injury by decreasing oxidation, suppressing cytokine action, refolding damaged proteins, and decreasing apoptosis. I hypothesize that alpha-adrenergic blockade decreases heat shock protein levels, thus making the heart and vascular system vulnerable to injury from pathologic processes such as ischemia, hypertension, oxidation or inflammation. Similarly, poor cardiovascular outcomes with calcium-channel blockers might be due to decreased expression of heat shock proteins.
References
-
- ALLHAT Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chorthalidone. JAMA. 2000;283:1967–1975. - PubMed
-
- Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb SR, Shah PM, Saunders R, Fletcher R, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547–1552. - PubMed
-
- Benjamin IJ, McMillan DR. Stress (heat shock) proteins – molecular chaperones in cardiovascular biology and disease. Circ Res. 1998;83:117–132. - PubMed
LinkOut - more resources
Full Text Sources
